|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
110.01(B) |
Last
Volume: |
507,716 |
Avg
Vol: |
759,306 |
52
Week Range: |
$692.45 - $1071.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
Total People Sold |
7 |
14 |
16 |
18 |
Total Sell Transactions |
18 |
45 |
67 |
128 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Brown Michael S |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
643 |
|
- |
|
Sing George L |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
115,415 |
|
- |
|
Sing George L |
Director |
|
2020-01-02 |
4 |
AS |
$371.98 |
$5,579,700 |
D/D |
(15,000) |
115,095 |
|
54% |
|
Sing George L |
Director |
|
2020-01-02 |
4 |
OE |
$24.41 |
$366,150 |
D/D |
15,000 |
130,095 |
|
- |
|
Poon Christine A |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
1,433 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
1,830 |
|
- |
|
Zoghbi Huda Y |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
643 |
|
- |
|
Bassler Bonnie L |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
643 |
|
- |
|
Coles N Anthony |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
643 |
|
- |
|
Goldstein Joseph L |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
10,643 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-12-20 |
4 |
OE |
$30.63 |
$12,252 |
D/D |
400 |
12,597 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-12-16 |
4 |
D |
$375.31 |
$47,289 |
I/I |
(126) |
2,200 |
|
- |
|
Brown Michael S |
Director |
|
2019-12-13 |
4 |
AS |
$372.75 |
$1,495,968 |
D/D |
(4,000) |
323 |
|
- |
|
Brown Michael S |
Director |
|
2019-12-13 |
4 |
OE |
$273.67 |
$1,094,680 |
D/D |
4,000 |
4,323 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-12-13 |
4 |
AS |
$373.26 |
$19,494,489 |
D/D |
(51,842) |
304,485 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-12-13 |
4 |
AS |
$374.82 |
$632,665 |
D/D |
(1,682) |
12,197 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2019-12-12 |
4 |
D |
$377.16 |
$61,085,965 |
D/D |
(161,963) |
474,499 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2019-12-12 |
4 |
OE |
$21.25 |
$6,638,500 |
D/D |
312,400 |
571,708 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-12-12 |
4 |
D |
$377.16 |
$47,964,192 |
D/D |
(127,172) |
444,109 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-12-12 |
4 |
OE |
$21.25 |
$5,212,519 |
D/D |
245,295 |
521,876 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-12-12 |
4 |
D |
$377.16 |
$21,050,431 |
D/D |
(55,813) |
356,327 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-12-12 |
4 |
OE |
$21.25 |
$2,287,669 |
D/D |
107,655 |
412,140 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-12-12 |
4 |
D |
$377.16 |
$534,813 |
D/D |
(1,418) |
13,879 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-12-12 |
4 |
OE |
$52.03 |
$161,293 |
D/D |
3,100 |
15,297 |
|
- |
|
Murphy Andrew J |
EVP ResearchOfficer |
|
2019-12-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,212 |
|
- |
|
2430 Records found
|
|
Page 35 of 98 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|